<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563302</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 481464-CS1</org_study_id>
    <nct_id>NCT01563302</nct_id>
  </id_info>
  <brief_title>Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers</brief_title>
  <official_title>A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of
      patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will
      be enrolled into the dose-expansion cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2012</start_date>
  <completion_date type="Actual">March 23, 2016</completion_date>
  <primary_completion_date type="Actual">March 23, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of IONIS-STAT3Rx in patients with Advanced Cancers</measure>
    <time_frame>Approximately 28 days after last dose of IONIS -STAT3Rx</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) of IONIS-STAT3Rx in patients with Advanced Cancers.</measure>
    <time_frame>Approximately 28 Days</time_frame>
    <description>Highest dose level at which no more than 1 out of 6 patients develops a DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical activity of IONIS-STAT3Rx</measure>
    <time_frame>Approximately 28 Days after last dose of IONIS-STAT3Rx</time_frame>
    <description>Measured by RECIST in the study population who have measurable disease or relevant disease specific response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Approximately 28 days after last dose of IONIS-STAT3Rx</time_frame>
    <description>Maximum observed drug concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAT3 and other biomarkers</measure>
    <time_frame>Approximately 28 days after last dose of IONIS-STAT3Rx</time_frame>
    <description>The effect of treatment with IONIS-STAT3Rx on phospho-STAT3 and other biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Approximately 28 days after last dose of IONIS-STAT3Rx</time_frame>
    <description>Time taken to reach Cmax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Advanced Cancers</condition>
  <condition>DLBCL</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-STAT3Rx</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-STAT3Rx</intervention_name>
    <description>Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>ISIS 481464</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic
             therapy and for which no standard therapy exists

          -  Expansion cohort only: Advanced lymphoma confirmed by histopathology

          -  Measurable or evaluable disease according to RECIST for solid tumors or according to
             IWRC for NHL tumors

          -  ECOG Performance Status less than or equal to 2

          -  Life expectancy greater than 12 weeks in the opinion of the Investigator

        Exclusion Criteria:

          -  Any active or uncontrolled infection

          -  NYHA Grade II or greater congestive heart failure

          -  History of myocardial infarction within 6 months prior to screening

          -  Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4
             weeks prior to screening or 5 half-lives of the therapy, whichever is shorter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Hughes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ionis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Advanced Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

